SYNDAX PHARMACEUTICALS INC's ticker is SNDX and the CUSIP is 87164F105. A total of 139 filers reported holding SYNDAX PHARMACEUTICALS INC in Q3 2022. The put-call ratio across all filers is 0.09 and the average weighting 0.5%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q1 2024 | $98,770 | +20.1% | 4,150 | +9.0% | 0.00% | 0.0% |
Q4 2023 | $82,269 | +48.8% | 3,807 | 0.0% | 0.00% | +33.3% |
Q3 2023 | $55,278 | -26.7% | 3,807 | +5.7% | 0.00% | -25.0% |
Q2 2023 | $75,390 | +9.7% | 3,602 | +10.7% | 0.00% | 0.0% |
Q1 2023 | $68,724 | -17.9% | 3,254 | -1.1% | 0.00% | 0.0% |
Q4 2022 | $83,756 | +13.1% | 3,291 | +6.8% | 0.00% | 0.0% |
Q3 2022 | $74,036 | +24.9% | 3,081 | 0.0% | 0.00% | +33.3% |
Q2 2022 | $59,278 | +10.7% | 3,081 | 0.0% | 0.00% | +50.0% |
Q1 2022 | $53,548 | -81.3% | 3,081 | -76.4% | 0.00% | -50.0% |
Q4 2021 | $285,818 | +14.5% | 13,057 | 0.0% | 0.00% | 0.0% |
Q3 2021 | $249,519 | +11.3% | 13,057 | 0.0% | 0.00% | +33.3% |
Q2 2021 | $224,189 | +26.4% | 13,057 | +64.7% | 0.00% | 0.0% |
Q1 2021 | $177,315 | +0.5% | 7,930 | 0.0% | 0.00% | 0.0% |
Q4 2020 | $176,363 | +50.7% | 7,930 | 0.0% | 0.00% | +50.0% |
Q3 2020 | $117,047 | -0.4% | 7,930 | 0.0% | 0.00% | 0.0% |
Q2 2020 | $117,523 | +35.1% | 7,930 | 0.0% | 0.00% | 0.0% |
Q1 2020 | $86,992 | – | 7,930 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Aisling Capital Management LP | 1,025,000 | $19,588,000 | 3.91% |
Ghost Tree Capital, LLC | 575,000 | $10,988,000 | 3.21% |
Avidity Partners Management LP | 4,823,400 | $92,175,000 | 2.04% |
BVF INC/IL | 2,486,429 | $47,516,000 | 1.85% |
FRAZIER MANAGEMENT LLC | 1,188,135 | $22,705,000 | 1.82% |
Nantahala Capital Management | 2,657,159 | $50,778,000 | 1.60% |
Boxer Capital, LLC | 2,287,782 | $43,720,000 | 1.53% |
ACUTA CAPITAL PARTNERS, LLC | 206,126 | $3,939,000 | 1.39% |
SPHERA FUNDS MANAGEMENT LTD. | 750,603 | $14,344,000 | 1.20% |
PFM Health Sciences, LP | 1,856,738 | $35,482,000 | 1.04% |